Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Zoetis (ZTS) stock in plain English

Free brief · no signupStart here
ZTSPublished Nov 13, 2026
Zoetis Inc
Healthcare · Drug Manufacturers - Specialty & Generic
Sells prescription medicines, vaccines, parasiticides, and diagnostic tests for companion animals and livestock.
Assets:
29 manufacturing sitesproduces medicines and vaccines globally
Over 1,400 R&D staffresearches animal therapeutics and diagnostics
Companion animal focusdrives over 65 percent of revenue
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

67
OPS ScoreOperating finances
Latest quote
-5.59%$80.79
$32.83B
13.7×
$9.51B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ZTS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Zoetis (ZTS) do?

Zoetis Inc (ZTS) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells prescription medicines, vaccines, parasiticides, and diagnostic tests for companion animals and livestock. Operates dedicated animal health research, manufacturing plants, and direct sales teams across dozens of countries. It is worth $32.83B on the market and sold $9.51B over the last year.

Market cap
$32.83B
P/E ratio
13.7×
Annual sales
$9.51B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 13, 2026

Brands and businesses behind ZTS

  • Apoquel: Daily oral prescription medication for allergic dog itch, generating revenue through veterinary clinic sales.
  • Simparica Trio: Monthly chewable protecting dogs against heartworm, fleas, and ticks, sold via veterinary clinics and pet pharmacies.
  • Librela: Monthly injectable monoclonal antibody for canine osteoarthritis pain, earning revenue from clinic administrations.
  • Cytopoint: Injectable antibody therapy targeting canine skin allergies, earning recurring revenue through regular clinic visits.
  • Solensia: Monthly injectable monoclonal antibody treating feline osteoarthritis pain, sold directly to veterinary practices.
  • Revolution Plus: Topical parasiticide for cats preventing fleas, ticks, and worms, earning sales through veterinary prescriptions.

ZTS’s flags, in plain English

Each flag is a number from Zoetis’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Wide Gross Margin

Gross margin of 70.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earns Its Keep

Earns 57.1% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.

Fat Margins

Profit margin of 26.2%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Debt Is Driving

Heavy debt, 280% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about ZTS

How big is Zoetis?

Zoetis’ market cap is $32.83B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $9.51B: what customers paid the company over the last year, before any costs.

What is ZTS’s P/E ratio?

ZTS’s P/E ratio is 13.7×. Investors pay about 13.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ZTS?

Rival drug developers produce competing monoclonal antibodies and generic formulations that challenge key pet dermatology and osteoarthritis treatments. That is one risk on Zoetis’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Zoetis’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ZTS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card